Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
0,42 AUD | -6,67% | +18,31% | +21,74% |
Attività
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 51 | 01/01/11 |
David Fang
DFI | Director of Finance/CFO | - | 01/03/18 |
Florian Vogl
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/23 |
Deanne Miller
COO | Chief Operating Officer | 47 | 17/10/12 |
Frédéric Triebel
CTO | Chief Tech/Sci/R&D Officer | 69 | 12/12/14 |
Claudia Jacoby
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | - | |
Frank Fliegert
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | 01/01/18 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Russell Howard
CHM | Chairman | 74 | 08/05/13 |
Marc Voigt
CEO | Chief Executive Officer | 51 | 01/01/11 |
Anne Anderson
BRD | Director/Board Member | - | 14/02 |
Frédéric Triebel
CTO | Chief Tech/Sci/R&D Officer | 69 | 12/12/14 |
Pete Meyers
BRD | Director/Board Member | 55 | 12/02/14 |
Lis Boyce
BRD | Director/Board Member | - | 11/04/23 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 1 188 834 559 | 1 143 502 554 ( 96,19 %) | 0 | 96,19 % |
Coordinate società
Società del gruppo
Nome | Categoria e settore |
---|---|
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Part of Immutep Ltd., Immutep GmbH develops novel immunotherapy treatments for cancer and autoimmune disease. The private company is based in Leipzig, Germany. The CEOs of the German company are - Kaufmann, Marc Voigt, Deanne Miller. |
Biotechnology
|
Settore
Vendite per attività
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+21,74% | 326 Mln | |
+1,51% | 42,75 Mrd | |
+49,22% | 41,61 Mrd | |
+8,57% | 41,34 Mrd | |
-12,36% | 26,59 Mrd | |
+8,92% | 25,49 Mrd | |
-25,13% | 18,12 Mrd | |
+29,17% | 12,24 Mrd | |
-3,12% | 11,76 Mrd | |
+6,35% | 11 Mrd |
- Borsa valori
- Azioni
- Azione IMM
- Società Immutep Limited